AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M
AI Proteins and Bristol Myers Squibb (NYSE: BMY) have entered a Research Collaboration and Option Agreement to develop novel miniprotein-based therapeutics. AI Proteins will receive an upfront payment to discover and optimize miniproteins for two undisclosed targets. BMY has options for exclusive worldwide licensing and two additional targets, with potential milestone payments up to $400M plus royalties. The collaboration leverages AI Proteins' AI-driven platform to design small, high-affinity proteins that offer advantages over traditional antibody therapies, including better tissue penetration and rapid clearance.
AI Proteins e Bristol Myers Squibb (NYSE: BMY) hanno stipulato un Accordo di Collaborazione alla Ricerca e Opzione per sviluppare nuove terapie a base di miniproteine. AI Proteins riceverà un pagamento iniziale per scoprire e ottimizzare miniproteine per due target non divulgati. BMY ha opzioni per la licenza esclusiva mondiale e per due ulteriori target, con potenziali pagamenti per traguardi fino a $400M più royalty. La collaborazione sfrutta la piattaforma guidata dall'IA di AI Proteins per progettare piccole proteine ad alta affinità che offrono vantaggi rispetto alle terapie ad anticorpi tradizionali, tra cui una migliore penetrazione nei tessuti e una rapida eliminazione.
AI Proteins y Bristol Myers Squibb (NYSE: BMY) han firmado un Acuerdo de Colaboración en Investigación y Opción para desarrollar nuevas terapias basadas en miniproteínas. AI Proteins recibirá un pago inicial para descubrir y optimizar miniproteínas para dos objetivos no revelados. BMY tiene opciones para licencias exclusivas a nivel mundial y para dos objetivos adicionales, con pagos por hitos que podrían alcanzar hasta $400M más regalías. La colaboración aprovecha la plataforma impulsada por IA de AI Proteins para diseñar proteínas pequeñas de alta afinidad que ofrecen ventajas sobre las terapias tradicionales con anticuerpos, incluyendo una mejor penetración en los tejidos y una rápida eliminación.
AI Proteins와 Bristol Myers Squibb (NYSE: BMY)는 새로운 미니 단백질 기반 치료제 개발을 위한 연구 협력 및 옵션 계약을 체결했습니다. AI Proteins는 두 개의 비공개 목표를 위해 미니 단백질을 발견하고 최적화하기 위해 선불금을 받게 됩니다. BMY는 전 세계 독점 라이선스 및 두 개의 추가 목표에 대한 옵션을 가지며, 잠재적인 마일스톤 지급은 $400M까지 가능하며 로열티도 포함됩니다. 이 협력은 AI Proteins의 AI 기반 플랫폼을 활용하여 전통적인 항체 치료제에 비해 장점이 있는 작은 고친화성 단백질을 설계합니다. 여기에는 더 나은 조직 침투 및 빠른 청소가 포함됩니다.
AI Proteins et Bristol Myers Squibb (NYSE: BMY) ont conclu un Accord de Collaboration en Recherche et Option pour développer de nouvelles thérapies basées sur des miniprotéines. AI Proteins recevra un paiement initial pour découvrir et optimiser des miniprotéines pour deux cibles non divulguées. BMY a des options pour des licences exclusives mondiales et deux cibles supplémentaires, avec des paiements d'étape potentiels pouvant atteindre jusqu'à $400M plus des redevances. La collaboration exploite la plateforme guidée par l'IA d'AI Proteins pour concevoir de petites protéines à forte affinité qui offrent des avantages par rapport aux thérapies traditionnelles par anticorps, y compris une meilleure pénétration des tissus et une élimination rapide.
AI Proteins und Bristol Myers Squibb (NYSE: BMY) haben eine Forschungskooperations- und Optionsvereinbarung zur Entwicklung neuartiger miniproteinbasierter Therapeutika getroffen. AI Proteins erhält eine Vorauszahlung, um Miniproteine für zwei nicht offengelegte Ziele zu entdecken und zu optimieren. BMY hat Optionen für exklusive weltweite Lizenzen und zwei zusätzliche Ziele, mit möglichen Meilensteinzahlungen von bis zu $400M sowie Lizenzgebühren. Die Zusammenarbeit nutzt die von KI gesteuerte Plattform von AI Proteins zur Gestaltung kleiner, hochaffiner Proteine, die Vorteile gegenüber herkömmlichen Antikörpertherapien bieten, einschließlich besserer Gewebepenetration und schnellerer Elimination.
- Secured collaboration agreement with major pharmaceutical company Bristol Myers Squibb
- Deal value up to $400M plus royalties on net sales
- Immediate upfront cash payment received
- Multiple revenue streams: upfront payment, milestone payments, and potential royalties
- Option for additional target expansion providing further growth potential
- Specific financial terms of upfront payment not disclosed
- Target proteins remain undisclosed, adding uncertainty to development prospects
- Milestone payments are contingent on achieving development goals
Insights
This collaboration marks a significant strategic move for Bristol Myers Squibb, expanding their therapeutic pipeline with innovative miniprotein technology. The
The deal includes options for four targets total, providing BMY with flexibility to expand the collaboration based on initial results. The AI-driven approach to protein design could significantly accelerate drug development timelines and reduce costs compared to traditional discovery methods. While early-stage, this partnership demonstrates BMY's commitment to advancing their pipeline through cutting-edge technology platforms.
This deal strengthens BMY's position in the competitive biologics space, particularly as the industry shifts toward smaller, more efficient therapeutic molecules. The
The collaboration aligns with industry trends toward AI-driven drug discovery and development of alternative protein therapeutics. This could provide BMY with a competitive advantage in developing more cost-effective and accessible biological therapies.
Under this collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize miniproteins against targets of interest to Bristol Myers Squibb. These de novo designed miniproteins, characterized by their small size and high affinity, have the potential to offer significant advantages over traditional antibody-based therapies, including improved tissue penetration and rapid clearance.
“We are excited to partner with Bristol Myers Squibb to bring our cutting-edge protein design technology to the clinic,” said Chris Bahl, PhD, President, CSO and Founder of AI Proteins. “Our platform combines AI, synthetic biology, and laboratory automation to rapidly design and optimize novel miniproteins with ideal drug-like properties. By combining our expertise in protein engineering with Bristol Myers Squibb’s deep knowledge of pharmaceutical development, we aim to create a new generation of targeted therapies that can transform patient outcomes.”
Under the terms of the agreement, AI Proteins will receive an upfront cash payment for the collaboration under which the company will discover and optimize miniproteins for two undisclosed targets. Bristol Myers Squibb has an option for an exclusive worldwide license to these miniproteins as well as two additional target options in exchange for an expansion fee and potential development, regulatory, and commercial milestone payments valued up to
About AI Proteins
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203759386/en/
Michelle Long
Head of Human Resources
michelle.long@aiproteinstx.com
+1 617-319-2342
Source: AI Proteins, Inc.
FAQ
What is the total value of AI Proteins' collaboration with Bristol Myers Squibb (BMY)?
How many initial targets are included in the BMY collaboration agreement?
What advantages do AI Proteins' miniproteins offer over traditional antibody therapies?
What rights does Bristol Myers Squibb (BMY) receive in the collaboration?
